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Abstract
Background: Neuroenhancement is the use of substances by healthy subjects to enhance mood or cognitive function. The
prevalence of neuroenhancement among Swiss university students is unknown. Investigating the prevalence of
neuroenhancement among students is important to monitor problematic use and evaluate the necessity of prevention
programs.
Study aim: To describe the prevalence of the use of prescription medications and drugs of abuse for neuroenhancement
among Swiss university students.
Method: In this cross-sectional study, students at the University of Zurich, University of Basel, and Swiss Federal Institute of
Technology Zurich were invited via e-mail to participate in an online survey.
Results: A total of 28,118 students were contacted, and 6,275 students completed the survey. Across all of the institutions,
13.8% of the respondents indicated that they had used prescription drugs (7.6%) or drugs of abuse including alcohol (7.8%)
at least once specifically for neuroenhancement. The most frequently used prescription drugs for neuroenhancement were
methylphenidate (4.1%), sedatives (2.7%), and beta-blockers (1.2%). Alcohol was used for this purpose by 5.6% of the
participants, followed by cannabis (2.5%), amphetamines (0.4%), and cocaine (0.2%). Arguments for neuroenhancement
included increased learning (66.2%), relaxation or sleep improvement (51.2%), reduced nervousness (39.1%), coping with
performance pressure (34.9%), increased performance (32.2%), and experimentation (20%). Neuroenhancement was
significantly more prevalent among more senior students, students who reported higher levels of stress, and students who
had previously used illicit drugs. Although ‘‘soft enhancers’’, including coffee, energy drinks, vitamins, and tonics, were used
daily in the month prior to an exam, prescription drugs or drugs of abuse were used much less frequently.
Conclusions: A significant proportion of Swiss university students across most academic disciplines reported
neuroenhancement with prescription drugs and drugs of abuse. However, these substances are rarely used on a daily
basis and more sporadically used prior to exams.
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Introduction
In recent years, there has been growing public awareness of
neuroenhancement, defined as the use of prescription drugs or
other psychoactive substances by healthy individuals who try to
improve their cognitive function or mood [1–4]. People may
use potentially enhancing substances in situations of perfor-
mance pressure if they are afraid that they will not fulfill
others’ or their own performance expectations [5]. Students
appear to be at high-risk for using enhancing substances [2,6–
8]. Pharmacological interventions may affect the cognitive
performance or mental state of a person [3]. The purpose of
neuroenhancement is to improve cognitive function and
emotional and motivational skills [9]. Several studies have
reported that individuals seek neuroenhancement to enhance
both cognitive function (e.g., alertness, attention, concentra-
tion, and memory) and psychological function (e.g., mood and
sleep), which may indirectly enhance cognitive performance
[10,11]. Many studies in the field of neuroenhancement have
only focused on the misuse of stimulant drugs, such as
methylphenidate and amphetamines [2,6,12,13], and have
not investigated sedative drugs, which can have at least an
indirect impact on cognitive performance. Prescription drugs,
as well as alcohol and illicit drugs of abuse that are taken with
the intent of improving mental performance, are subsumed
under the term ‘‘neuroenhancers,’’ whereas non-prescription
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drugs, food supplements, and caffeine-containing products can
be regarded as ‘‘soft enhancers’’ [14].
Some evidence suggests that neuroenhancement is widespread
within academic institutions. A non-representative survey in Nature
showed that 20% of all academics had taken methylphenidate,
modafinil, or beta-blockers to improve cognitive performance
[6,7,15]. Measures of the prevalence of neuroenhancement in the
United States vary between 5% and 9% for high school students
and between 5% and 35% for college students [12,13,16,17]. The
prevalence rates reported in these studies must be viewed critically
because many studies have failed to ask participants about the
reason why possible neuroenhancing substances are taken.
Therefore, the recreational use of substances may have also
contributed to these results [12]. The motivation for the non-
medical use of prescription drugs or the use of alcohol and illicit
drugs varies widely. The mean lifetime prevalence for ‘‘study
drugs’’ in young adults in the United States is approximately 7%,
and the past year prevalence of the illicit use of prescription
stimulants is estimated to be 4% [18].
Several studies in Europe, the United States, and Australia have
estimated the prevalence of neuroenhancement, although the
findings differ greatly. In Europe, neuroenhancement does not
appear to be as common as in the United States or Canada
[2,14,19,20]. Among German students, 1.55% used prescription
stimulants, and 2.6% used illegal stimulants for neuroenhance-
ment [2]. In the same study, male students and students with poor
grades used more neuroenhancing substances than female students
and students with good grades [2]. More recent studies, however,
have reported a higher prevalence of neuroenhancement among
students in Germany. A study of German university students
reported a period prevalence rate of neuroenhancement of 7%,
including the ‘‘time during studies’’ [21]. Another study found a
12-month prevalence of 20% for students when caffeine tablets
were included as neuroenhancers [22]. A weakness of this study,
however, was the definition of neuroenhancement and a
questionable statistical approach because a 20% past year use in
students appears very high.
Estimating how many students effectively practice neuroen-
hancement is difficult. Published data on neuroenhancement
among Swiss students is lacking. According to a recent study, Swiss
psychiatrists and general practitioners are faced with requests for
neuroenhancers an average of once or twice per year, and nearly
half of them (49.1%) reported that they decided on such requests
pragmatically on a case-by-case basis [23].
Healthy individuals are usually unaware of the possible side
effects of consuming prescription drugs for neuroenhancement.
Even the known side effects of alcohol and illicit psychoactive
substances can vary individually. Several studies of possible
neuroenhancing substances showed that they exerted no or
minimal effects on cognitive function. Positive effects on concen-
tration, alertness, and attention were only documented for
stimulants and modafinil [20,24–26]. Additionally, no long-term
studies of the negative effects of prescription drugs (e.g.,
investigations of tolerance and abuse potential in healthy
individuals) have been performed [27]. However, Wulf (2009)
introduced the theoretical view that neuroenhancement may
disturb self-efficacy expectations because performance and out-
comes become increasingly more attributed to the use of
supposedly enhancing substances [28].
Students’ and physicians’ perceptions of neuroenhancement are
rather negative. An Australian study showed that students were
often skeptical about the potential benefits of stimulants with
regard to the enhancement of cognitive function, and they were
afraid of unknown side effects, mental health issues, and
psychological dependence [29]. In a Canadian study, physicians
did not feel comfortable prescribing cognition-enhancing sub-
stances for young adults, even if a hypothetical medication exists
that is safe, effective, and without significant adverse side effects
[30]. Students who are experienced with neuroenhancement did
not perceive a difference (28% of respondents) or could not decide
whether a difference exists (28%) between caffeinated substances
and illicit or prescription stimulants, such as amphetamines or
methylphenidate [31].
The relationship between experienced performance pressure
and neuroenhancement has previously been investigated. In 2010,
34% of Swiss employees felt that they perceived chronic stress,
whereas in the same survey in 2000, only 7% of the participants
reported frequent high levels of stress [32]. The authors estimated
that in the last 12 months, 6% of Swiss employees had taken
substances for cognitive enhancement, and 15% had consumed
substances to relax and switch off after stressful days at work [32].
In a German study, 31% of students felt strong performance
pressure and were afraid of being unable to cope with demands
concerning their studies [14].
Which substances are used for neuroenhancement is poorly
understood. Medications to treat attention deficit disorder (ADD)
and attention-deficit/hyperactivity disorder (ADHD), such as
methylphenidate and the wake-promoting agent modafinil, are
the pharmaceuticals that are generally discussed in the bioethical
debate on neuroenhancement [7,24,33]. ADHD is the most
prevalent neuropsychiatric disorder in childhood [15]. In Swit-
zerland, the number of people who obtain ADHD medications
increased by 42% from 2006 to 2009, and the quantity of
methylphenidate used per person and per year increased from
5,600 mg to 6,200 mg, respectively [34]. A history of multiple
substance use is a risk-factor for the non-medical use of
methylphenidate [35]. The co-occurrence of illicit drug use and
the non-medical use of prescription stimulants and the occurrence
of ADD/ADHD patients who misuse their medication have also
been reported among college students [8,36]. Based on a study of
United States college students, Novak and colleagues estimated
that one-quarter of ADD/ADHD patients consume their medi-
cations in a manner that differs from the intended prescription of
the medication [36]. Different medications are used to treat ADD/
ADHD in different countries. In the United States, dextroam-
phetamine and mixed amphetamine salts are used to treat ADD/
ADHD, whereas these medications are not licensed in Switzerland
or Germany [37,38]. As a result, methylphenidate is the most
commonly prescribed ADD/ADHD medication in Switzerland
[34].
To overcome the lack of empirical data on neuroenhancement
among Swiss university students, we created a cross-sectional
online survey to investigate whether the prevalence of use was
similar to the use in other countries and explore the relevant
factors, such as study-related stress, possible arguments for
neuroenhancement, sources of supply, and preliminary attitudes
about neuroenhancement. The students were asked to report their
non-medical use of prescription drugs and drugs of abuse and the
purpose of consuming each substance. In contrast to earlier
studies, we also inquired about both the recreational and
neuroenhancement uses of alcohol. The aim of the present study
was to identify several substances that are used by students to
improve cognitive performance and mood and describe the extent
of prescription drug, alcohol, and illicit psychoactive substance use
for the purpose of neuroenhancement among Swiss university
students. Investigating the prevalence of neuroenhancement
among student populations is important to monitor problematic
use and evaluate the necessity of prevention programs.
Neuroenhancement among Swiss University Students
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Methods
Study procedures and sample
This social-empirical cross-sectional study was performed from
December 2012 to January 2013. A total of 28,118 students from
three different educational institutions in Switzerland were
contacted by e-mail and asked to complete an online questionnaire
about the use of psychoactive substances. The study was approved
by the ethics committee of the Philosophical Faculty of the
University of Zurich and Ethics Committee of Basel. The
informational message distributed to potential subjects invited
them to participate, explained the rationale for the study, and
stated that the study was reviewed by the ethics committee of the
Philosophical Faculty of the University of Zurich and the Ethics
Committee of Basel, who declared no objection. The message to
the participants also provided a web link that provided more
information about the study: the study was absolutely voluntary,
personal data would be anonymized and stored on a secure server,
and the participants had the right to withdraw from the study at
any time without any consequences except their exclusion from
the drawing for a tablet computer. The participants were also
allowed to ask the study coordinator questions. Informed consent
was recorded when the participants left the study information web
page and began the survey by clicking on the survey start button.
The survey was conducted among students at the University of
Zurich (UZH), University of Basel (UniBas), and Swiss Federal
Institute of Technology Zurich (ETHZ). The contacts established
through the mailing lists of each university included 5,000 students
from UZH, 12,337 students from ETHZ, and 10,781 students
from UniBas. The students were told that the aim of the study was
to determine whether the use of neuroenhancing substances was
common at Swiss universities. The term ‘‘brain doping’’ was
defined as the intake of any substances to enhance cognitive
function. The participants were also informed that they could win
a tablet computer by providing their e-mail address, which was
stored separately from the survey data. The final sample size was
6,275 students.
Measures
The questionnaire was specifically designed for the present
study at the Swiss Research Institute for Public Health and
Addiction. Some questions were taken from existing question-
naires on neuroenhancement (e.g., Middendorf et al. [14]), and
questions concerning the consumption patterns and consumption
frequency of different substances were based on the recommen-
dations of Swiss Addiction Monitoring [39]. At the beginning of
the questionnaire, neuroenhancement was defined as the use of
prescription drugs or other psychoactive substances (e.g., drugs of
abuse, such as cannabis) to directly or indirectly enhance brain
function (e.g., concentration, alertness, and a reduction of
nervousness). The questionnaire included additional questions on
the use of coffee, caffeine tablets, and herbal products. The
participants were informed that completion of the questionnaire
would take approximately 15 min. The participants were first
asked to indicate their university, major, semester of study, age,
gender, and whether they studied full-time or part-time. The
participants were also asked to rate the degree of stress and
performance pressure they felt with regard to education, work,
leisure, and family on a scale from 1 to 5. The subjects were then
asked whether they had heard that prescription drugs, drugs of
abuse, and other substances are used to enhance cognitive
function. The subjects were also asked whether they had ever
used one or more of the substances that had been listed without
having a clear medical indication for doing so (i.e., lifetime
prevalence of non-medical use for recreational or neuroenhance-
ment purposes). If the students responded that they had used a
substance without a clear medical indication, then they had to
indicate the purpose of use (e.g., recreationally at parties, cognitive
enhancement for studying, in stressful situations, during exams, to
enhance performance, or to learn more efficiently or for longer
periods of time). For each substance, the participants also had to
indicate the frequency of use within the last 30 days prior to the
last exam and whether their expectations regarding the medica-
tion’s effects were met. These questions were asked for the
following groups of substances: methylphenidate, modafinil,
activating antidepressants including selective serotonin reuptake
inhibitors (SSRIs), anti-dementia agents, sedatives/hypnotics,
herbal sedatives (e.g., St. John’s Wort, common valerian), beta-
blockers, vitamins and tonics (e.g., Gingko biloba, zinc, vitamin pills),
alcohol, cannabis, cocaine, amphetamines (amphetamine, meth-
amphetamine), ecstasy (methylenedioxymethamphetamine), c-
hydroxybutyrate/c-butyrolactone (GHB/GBL; liquid ecstasy),
coffee, caffeine tablets, and energy drinks. A series of questions
asked about problems that occurred as a result of the consumption
of substances for the purpose of neuroenhancement. The
participants were asked whether they experienced problems with
education, family, friends, police, finances, or health. Health-
related questions asked whether the subjects had experienced the
following symptoms: passing out, anxiety and panic attacks,
aggressiveness, depressive symptoms, loss of appetite, increased
sweating, sleeping disorders, heart palpitations, tachycardia,
headache, nervousness, or accidents. The students were asked to
indicate the source from which they obtained the prescription
drugs (e.g., Internet, physician, pediatrician, pharmacy, person
with a prescription, dealer, parents, and colleagues). According to
a survey among German university students [14], the subjects
were then asked more specifically about their motives for brain
doping (e.g., to learn more quickly and more efficiently, to reduce
nervousness and performance anxiety, to increase performance, to
relax and improve sleep, to reduce high performance pressure, to
cope with competitive pressure, curiosity and experimentation,
and because others use it) and whether they generally used these
substances for exam preparation, during exams, or in stressful life
situations. This question was asked for all of the substances,
including soft enhancers such as coffee or energy drinks.
The students were asked to report how many people they knew
were using prescription drugs or psychoactive substances for
studying. Additionally, the subjects were asked whether they had
ever been diagnosed with a psychiatric disorder, including ADHD,
depression, anxiety, and other disorders, and whether they were
regularly taking any medications. The last question was about
personal justifiable motives for the consumption of enhancing
substances. The students could choose one or more options that
they believed justified the use of neuroenhancers (e.g., suppress
fatigue, manage sleeping disorders, manage time, manage
conflicts, address the pressure of competition, manage nervous-
ness, manage poor mood, alleviate pain, enhance charisma, treat
depression, treat influenza, and medical advice), or they could say
that neuroenhancement was unacceptable in any situation.
Definitions and statistical analyses
The analyses were performed using SPSS 20 for Windows.
Descriptive statistics were used to evaluate the questions. Cross
tables and Pearson’s x2 tests were used to test for significant group
differences in the prevalence of use. Three different categories
were used. The category ‘‘prescription drugs’’ included methyl-
phenidate, modafinil, antidepressants, anti-dementia agents, sed-
atives, and beta-blockers. The category ‘‘drugs of abuse including
Neuroenhancement among Swiss University Students
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alcohol’’ included all substances of abuse, including alcohol,
cannabis, cocaine, amphetamines, ecstasy, and GHB/GBL. The
term ‘‘neuroenhancement’’ is used here for the reported use of
both prescription drugs and drugs of abuse, including alcohol, if
the students reported that they had used any of these substances to
enhance cognitive function. A third category called ‘‘soft
enhancers’’ [14] included herbal sedatives, vitamins and tonics,
coffee, caffeine tablets, and energy drinks. These substances were
also taken by the students with the purpose of improving mental
performance, although they were available in drug stores without a
prescription. Soft enhancers were not included in the neuroen-
hancement drug category.
Results
Sample description
Response rates and participant characteristics are shown in
Table 1. The participants were 17 to 68 years old, with an average
age of 23.18 years. The number of semesters completed ranged
from one to 33, with an average of five semesters. Gender was
equally distributed among the entire sample. Most of the
respondents from UZH and UniBas were women, whereas the
majority of the ETHZ students were men. Most of the participants
had a full-time study workload. The students from ETHZ were
primarily full-time students and were less frequently employed
during their studies. Students in psychology, law, economics, and
sports were frequently working in addition to studying.
Prevalence rates of neuroenhancement
The majority of the respondents (93.7%) reported that they had
heard that prescription drugs, drugs of abuse, and other substances
could be used to enhance cognitive function. Of the study
population, 868 subjects (13.8%) had already used prescription
drugs or drugs of abuse, including alcohol, at least once with the
purpose of enhancing cognitive function (Table 2). Prescription
drugs had been used in 7.6% of the sample, and drugs of abuse,
including alcohol, had been used by 7.8% (Table 2). Only 1.5% of
the respondents reported using both prescription drugs and drugs
of abuse for neuroenhancement purposes. As shown in Table 3,
the most frequently used prescription drugs for academic
performance enhancement were methylphenidate and sedatives.
Alcohol and cannabis were the most frequently used drugs of
abuse, whereas stimulant drugs, such as amphetamines, cocaine,
and ecstasy, were rarely used for the purpose of neuroenhance-
ment. Among the soft enhancers, half of the students used coffee,
and one-third used energy drinks explicitly to enhance their
cognitive function. The use of caffeine tablets for this purpose was
not very prevalent. The daily use of substances for neuroenhance-
ment in the month prior to an exam was only reported for soft
enhancers, such as coffee, vitamins and tonics, and energy drinks,
but not for prescription drugs or drugs of abuse (Table 3). One-
third of the students (33%) reported daily use of at least one soft
enhancer, whereas only 1.8% reported the daily use of a
prescription drug or drug of abuse, including alcohol, for the
purpose of neuroenhancement. The majority of the students who
took any substance for neuroenhancement reported that such
substances met their expectations with regard to the anticipated
effects, with the exception of anti-dementia agents, for which most
of the students were dissatisfied (Table 3). More than half of the
respondents (52.7%) used neuroenhancement or soft enhancers for
exam preparation, and 24.3% used any of these substances during
the exam itself. Among the students, 19.8% also noted that they
used neuroenhancement or soft enhancers during stressful life
situations in general. Students who used neuroenhancers (n=868)
more frequently reported the use of enhancing substances,
including soft enhancers, during exam preparation (69.9%), exams
(37.7%), or stressful life situations in general (36.2%) compared
with students who never used neuroenhancers and only used
vitamins and tonics, caffeine-containing products, or herbal
products to cope with stressful situations.
In our sample, 5.8% of the students (6.9% of men and 4.7% of
women) reported the non-medical use of methylphenidate for
either neuroenhancement or recreational purposes. The lifetime
prevalence rates of methylphenidate use for neuroenhancement
were 4.6% for men and 3.5% for women. The lifetime prevalence
of recreational methylphenidate use was significantly higher
Table 1. Response rates and participant characteristics (N= 6275).
Institution
UZH1 (n=404) ETHZ2 (n=3347) UniBas3 (n=2524) Total (N=6275)
Response rate 8.1% (404 of 5000) 27.1% (3347 of 12337) 23.4% (2524 of 10781) 22.3% (6275 of 28118)
Gender
Male 25.5% (103) 61.4% (2055) 41% (1034) 50.9% (3192)
Female 74.5% (301) 38.6% (1292) 59% (1490) 49.1% (3083)
Mean age (years) 24.85 (SD=5.42) 22.37 (SD= 2.65) 23.98 (SD= 5.01) 23.18 (SD= 4.06)
Number of semesters 6.19 (SD=4.01) 4.86 (SD= 2.99) 5.5 (SD= 3.47) 5.21 (SD= 3.29)
Study workload
Full-time 84.7% (342) 98.2% (3287) 87.2% (2200) 92.9% (5829)
Part-time 15.3% (62) 1.8% (60) 12.8% (324) 7.1% (446)
Employment during studies
Yes 71.3% (288) 31.6% (1058) 59% (1488) 45.2% (2834)
No 28.7% (116) 68.4% (2289) 41% (1036) 54.8% (3241)
1University of Zurich.
2Swiss Federal Institute of Technology Zurich.
3University of Basel.
doi:10.1371/journal.pone.0077967.t001
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among men (3.1%) than among women (1.5%; p=0.007). The
nasal administration of methylphenidate was more common
among recreational users (13.4%) compared with students who
used it for neuroenhancement purposes (6%). As shown in Table 2,
male students used drugs of abuse for neuroenhancement purposes
significantly more often than female students. Female students
used soft enhancers more often for enhancing purposes (herbal
sedatives, p,0.001; vitamins and tonics, p,0.001; coffee,
p=0.001; caffeine tablets, p=0.001; energy drinks, p,0.001),
whereas male students were more experienced with the recrea-
tional use of methylphenidate (p=0.007), vitamins and tonics
(p=0.005), caffeine tablets (p,0.001), and energy drinks
(p,0.001).
The prevalence rate of neuroenhancement varied slightly across
different study majors. Almost one in five architecture students
had used neuroenhancers to improve cognitive function or mood
(Table 4). A high lifetime prevalence of neuroenhancement was
also found in journalism and communication, chemistry, and
economics students. Mathematics and sports students were less
experienced with neuroenhancement (Table 4).
Neuroenhancement and experiences with illicit drugs of
abuse
The lifetime prevalence of illicit drug use for any purpose was
44.3% when including cannabis and 7.8% when excluding
cannabis (Table 4). Across academic disciplines, the prevalence
rate of illicit drug use ranged from 34.1% to 60.6% when cannabis
was included and from 3% to 14.1% when cannabis was excluded
(see Table 4 for academic discipline results). The primary purpose
of using illicit drugs was recreational rather than for neuroen-
hancement purposes (Table 3). Students who had experience with
illicit drugs of abuse used prescription drugs or drugs of abuse for
neuroenhancement significantly more often than students who had
never tried illicit substances (Table 5). These findings were
consistent across all of the study sites.
One-third of the students who used neuroenhancers (33.9%)
knew one or two people who already used prescription drugs to
improve their cognitive function. Only 40.1% of the students who
experienced neuroenhancement did not know anyone who took
prescription drugs for neuroenhancement purposes. Of the
students who never used neuroenhancement, 64.5% reported
not knowing anyone who consumed prescription drugs to enhance
academic performance. Half of the students who used neuroen-
hancement (49.3%) knew at least one person who had tried to
enhance cognitive function by using drugs of abuse, whereas only
29.3% of the non-users knew people who had done so. Of the
students who used neuroenhancement, 70.9% knew eight or more
people who had used soft enhancers, such as coffee or energy
drinks. Additionally, 57.1% of the students without neuroenhance-
ment knew at least eight people who had used soft enhancers to
improve cognitive performance.
Perceived stress and neuroenhancement
Students who reported higher levels of performance pressure
with regard to education, work, leisure, or family were also more
experienced with neuroenhancement. Of the respondents who
rated their stress highest for work, 28% had consumed prescription
drugs or drugs of abuse for neuroenhancement purposes. Of the
students with high subjective performance pressure in the area of
education, 18.2% reported neuroenhancement, although 14.6% of
the students who felt no performance pressure at all also practiced
neuroenhancement. Students who reported experiencing lower
Table 2. Lifetime prevalence of neuroenhancement according to substance categories and study site (N= 6275).
Institution
UZH1 (n=404) ETHZ2 (n=3347) UniBas3 (n=2524) Total (N=6275)
Prescription drugs
Men 12.6% (13) 6.6% (135) 8.3% (86) 7.3% (234)
Women 12% (36) 6% (78) 8.5% (127) 7.8% (241)
Total 12.1% (49) 6.4% (213) 8.4% (213) 7.6% (475)
Drugs of abuse including alcohol
Men 11.7% (12) 8.5% (174)* 9.5% (98)** 8.9% (284)***
Women 8.3% (25) 6.3% (81) 6.6% (98) 6.6% (204)
Total 9.2% (37) 7.6% (255) 7.8% (196) 7.8% (488)
Prescription drugs AND drugs of abuse including alcohol
Men 1.9% (2) 1.6% (33) 1.8% (19) 1.7% (54)
Women 2.3% (7) 1% (13) 1.4% (21) 1.3% (41)
Total 2.2% (9) 1.4% (46) 1.6% (40) 1.5% (95)
Prescription drugs OR drugs of abuse including alcohol
Men 22.3% (23) 13.4% (276)* 16% (165) 14.5% (464)
Women 17.9% (54) 11.3% (145) 13.7% (204) 13.1% (404)
Total 19.1% (77) 12.6% (422) 14.6% (369) 13.8% (868)
*p,0.05,
**p,0.01,
***p,0.001, compared with women.
1University of Zurich.
2Swiss Federal Institute of Technology Zurich.
3University of Basel.
doi:10.1371/journal.pone.0077967.t002
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Table 3. Prevalence of neuroenhancement and consumption patterns of substances used for neuroenhancement (N= 6275).
All types of use Recreational use Use for neuroenhancement
Lifetime
prevalence
Lifetime
prevalence Lifetime prevalence
Last month
prior to exam
Daily use prior
to exam
Expectations
fulfilled1
Prescription drugs
Methylphenidate 5.8% (367) 2.3% (145) 4.1% (255) 2.6% (163) 0.4% (22) 67.5% (172)
Modafinil 0.4% (25) 0.1% (5) 0.3% (22) 0.2% (15) 0.04% (3) 68.2% (15)
Antidepressants 1.6% (97) 0.3% (17) 0.5% (32) 0.4% (26) 0.2% (14) 59.4% (19)
Anti-dementia agents 0.1% (8) — 0.1% (8) 0.1% (7) 0.03% (2) 37.5% (3)
Sedatives 5.8% (364) 3.4% (215) 2.7% (170) 2.1% (133) 0.2% (14) 75.9 (129)
Beta-blockers 1.7% (108) 0.5% (30) 1.2% (74) 0.7% (45) 0.1% (6) 70.3% (52)
Drugs of abuse including alcohol
Alcohol 93.4% (5688) 90.2% (5660) 5.6% (350) 5.1% (320) 0.4% (22) 87.1% (305)
Cannabis 45.1% (2741) 43.3% (2720) 2.5% (158) 1.8% (115) 0.6% (37) 93% (147)
Cocaine 4.3% (264) 4.2% (262) 0.2% (12) 0.1% (7) 0.02% (1) 75% (9)
Amphetamines 3.9% (239) 3.7% (231) 0.4% (26) 0.3% (17) 0.03% (2) 84.6% (22)
Ecstasy 5.6% (337) 5.2% (327) 0.1% (4) 0.02% (1) — 100% (4)
GHB/GBL 0.9% (56) 0.9% (54) — — — —
‘‘Soft enhancers’’ (non-prescription drugs, food supplements, caffeine-containing products, etc.)
Herbal sedatives2 29.1% (1804) 12.6% (793) 18.2% (1143) 13.2% (830) 1.4% (86) 63.9% (730)
Vitamins and tonics3 40.6% (2505) 25.1% (1575) 18.2% (1140) 14.9% (933) 5.2% (328) 67.3% (766)
Coffee 86.3% (5212) 75.4% (4735) 53.2% (3340) 49.1% (3081) 28.3% (1776) 84.9% (2834)
Caffeine tablets 7.4% (444) 3.2% (200) 4.4% (276) 2.6% (166) 0.3% (18) 69.2% (191)
Energy drinks 67.5% (4069) 53.8% (3375) 35.9% (2253) 29.7% (1862) 4% (250) 82.1% (1849)
1Percent of students who used neuroenhancement.
2St. John’s wort, common valerian.
3Gingko biloba, zinc, vitamin tablets.
doi:10.1371/journal.pone.0077967.t003
Table 4. Lifetime prevalence of neuroenhancement and experiences with illicit drugs of abuse by academic discipline (N= 6275).
Neuroenhancement Lifetime experience with illicit drugs of abuse2
Major discipline1
Prescription drugs OR drugs of abuse
including alcohol Including cannabis Excluding cannabis
Biology (n=385) 14.5% (56) 44.2% (170) 5.6% (21)
Chemistry (n= 205) 17.6% (36) 43.4% (89) 9.8% (19)
Medicine (n= 395) 16.2% (64) 46.6% (184) 7.3% (28)
Psychology (n= 339) 14.5% (49) 51.9% (176) 9.9% (32)
Journalism and communication (n= 66) 18.2% (12) 60.6% (40) 14.1% (9)
Law (n= 249) 14.5% (36) 43.4% (108) 9% (22)
Economics (n=321) 17.1% (55) 49.2% (158) 9.7% (30)
Architecture (n=321) 19.6% (63) 56.4% (181) 14.1% (43)
Sports (n= 229) 7% (16) 34.1% (78) 5.8% (13)
Mechanical engineering (n= 584) 10.6% (62) 38.2% (223) 6.8% (38)
Mathematics (n= 174) 8.6% (15) 36.2% (63) 6.6% (11)
Pharmaceutical sciences (n= 341) 16.1% (55) 37.5% (128) 6.1% (20)
Physics (n=209) 11.5% (24) 37.3% (78) 3% (6)
Environmental sciences (n=219) 11.4% (25) 45.2% (99) 10.9% (23)
Total (N= 6275) 13.8% (868) 44.3% (2777) 7.8% (491)
1Other (n= 2226): politics, veterinary medicine, theology, philosophy, history, literature, linguistics, art history, dental medicine, information technology, geography etc.
2Cocaine, amphetamines, ecstasy, GHB/GBL, with/without cannabis.
doi:10.1371/journal.pone.0077967.t004
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education- or work-related performance pressure reported a
higher lifetime use of illicit drugs of abuse. The most commonly
experienced side effects after consuming neuroenhancers were
nervousness (27.1%), sleeping disorders (26.4%), and headaches
(25%). The participants also reported experiencing depressive
states (18.1%), loss of appetite (17.9%), and tachycardia (15.8%).
Problems with family (6.3%) or friends (3.8%) caused by
neuroenhancement were uncommon. Some students had experi-
enced an anxiety attack (7.4%) or felt aggressive (6.6%) while
under the influence of neuroenhancers, and some students
reported problems with their education (5.1%) while using
neuroenhancers. Only a few students had financial problems
(2.4%), problems with the police (2.3%), accidents (0.9%), or
passed out (2.5%) because of the consumption of neuroenhancers.
Many students did not report problems related to neuroenhance-
ment (38.1%).
Source of supply
Of the participants who used prescription drugs or drugs of
abuse for neuroenhancement purposes, 15.4% received their
prescription drugs for neuroenhancement from a doctor. Other
students (14.7%) and people with a prescription (12.9%) were
another common source of neuroenhancement prescription drugs.
Of the respondents, 10.5% purchased their prescription drugs at a
pharmacy, and only 4.1% of the students purchased prescription
drugs or illicit drugs of abuse for neuroenhancement on the
Internet. One individual stated that he had received prescription
drugs from a pediatrician, and 5.9% of the respondents reported
that their parents were the source of the prescription drugs or illicit
drugs of abuse for neuroenhancement. The respondents reported
that they obtained prescription drugs to enhance cognitive
function from psychiatrists (6.3%) and also obtained prescription
drugs and illicit drugs of abuse for neuroenhancement from
dealers (8.1%).
Subjects with ADHD diagnosis
Forty-one of 109 (37.6%) students who had ever been diagnosed
with ADD/ADHD were taking medications regularly. Thirty-six
(33%) students with an ADD/ADHD diagnosis indicated that they
had misused methylphenidate. Ten students (9.2%) reported the
recreational use of methylphenidate, and 29 students reported
methylphenidate use for cognitive enhancement (26.6%).
When excluding subjects with an ADHD diagnosis, the
prevalence for methylphenidate use was 5.4% compared with
5.8% in the entire sample. The prevalence rates of recreational or
neuroenhancement use of methylphenidate were 2.2% and 3.7%,
respectively, when excluding subjects with ADHD compared with
2.3% and 4.1%, respectively, in the entire sample.
Arguments for/against neuroenhancement
Arguments for the use of neuroenhancers included increased
learning (66.2%), relaxation or sleep improvement (51.2%),
reduced nervousness (39.1%), coping with performance pressure
(34.9%), increased performance (32.2%), and experimentation
(20%). Of the students who were experienced with neuroenhance-
ment, only 9.8% mentioned competitive pressure and 2.8%
mentioned other people’s use of substances as motives for the use
of enhancing substances.
Many students would accept the consumption of prescription
drugs and drugs of abuse to enhance cognitive performance if the
use of these substances was based on professional medical advice
(44.5%) or the treatment of a disease (42.8%), a diagnosed
psychological disorder (38%), or a sleeping disorder (36.6%).
Motives such as enhancing cognition, alertness, and memory
(40%), reducing pain (37%), suppressing fatigue (43%), or
reducing nervousness (30.8%) would also justify neuroenhance-
ment. The use of substances solely to enhance charisma (1.5%) or
mood (5.4%), to solve conflicts (2.7%), or to manage the pressures
of competition (6.7%) and limited time (14.6%) was acceptable
only among a few students. Only 15.5% of the students reported
that they see no reason for neuroenhancement at all.
Discussion
The main finding of the present survey was that a significant
proportion of Swiss university students reported a lifetime use of
prescription drugs or drugs of abuse to enhance academic
performance. Additionally, this finding was consistent across three
different institutions and across study majors. Of the 6,275
respondents, 868 (13.8%) had experience with neuroenhance-
ment. The most commonly used substances were methylphenidate
(4.1%), sedatives (2.7%), alcohol (5.6%), and cannabis (2.5%).
Although neuroenhancement was used especially for exam
preparation (69.9%), the daily use of prescription drugs or drugs
of abuse as neuroenhancers was uncommon, even prior to an
exam.
The high lifetime prevalence rate of neuroenhancement found
in the present study depends on the definition of ‘‘neuroenhance-
ment,’’ which in our case also included drugs with sedative effects.
Clearly, sedatives are not used to directly enhance learning
processes, but they can influence academic performance in a
desirable way. A well-rested brain likely learns more efficiently.
Thus, for example, the consumption of cannabis or alcohol with
Table 5. Experience with neuroenhancement and illicit drugs of abuse (N= 6275).
Neuroenhancement
Lifetime experience with illicit drugs of abuse (n=2777) Never tried illicit drugs of abuse (n=3498)
Prescription drugs 10.8% (299)*** 5% (176)
Drugs of abuse including alcohol 13.1% (365)*** 3.5% (123)
Prescription drugs AND drugs of abuse
including alcohol
2.9% (81)*** 0.4% (14)
Prescription drugs OR drugs of abuse
including alcohol
21% (583)*** 8.1% (285)
*p,0.05,
**p,0.01,
***p,0.001, compared with people who never tried illicit drugs of abuse.
doi:10.1371/journal.pone.0077967.t005
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the purpose of calming oneself, turning off reoccurring thoughts,
and falling asleep would allow one to be more vigilant and increase
concentration the following morning. Thus, the use of alcohol and
cannabis in such a case could also be considered a form of
neuroenhancement. Only a few previous studies have included
sedative substances in their concept of neuroenhancement [14,19].
According to the definitions provided in earlier studies, we
performed a supplemental analysis in which we excluded all
sedatives, including alcohol and cannabis, and only included
methylphenidate, modafinil, antidepressants, anti-dementia
agents, beta-blockers, cocaine, and amphetamines in the neu-
roenhancement category. This analysis resulted in a considerably
lower overall prevalence of neuroenhancement (5.9%) in our
complete sample (Table 6).
The primary motivation of users was to learn more quickly and
more efficiently, which could be expected to result in enhanced
academic performance. Soft enhancers, including coffee, energy
drinks, vitamins and tonics, and herbal sedatives, are common
among students in daily life, and the use of these substances also
seems to be socially accepted, whereas neuroenhancement was
only considered justified in certain situations where people were
disadvantaged.
Methylphenidate was the most prevalent prescription drug used
for neuroenhancement in the present study. The numbers of
people who obtain ADD/ADHD medications and the amount of
medication in Switzerland have increased over recent years [34].
The present study included both healthy individuals and people
with a diagnosis of ADD/ADHD who misused their medication
who consumed prescription drugs and drugs of abuse for
neuroenhancement purposes. Misuse in patients is defined as the
intake of higher doses of the medications [8] than prescribed or
using another mode of application (intranasal or intravenous) than
the one prescribed by a doctor [36]. In the present study, the
recreational use of methylphenidate was more commonly associ-
ated with nasal administration (13.4%) compared with its use for
neuroenhancement purposes (6%). Previous surveys often exclud-
ed subjects with an ADD/ADHD diagnosis to prevent biasing
outcomes with regard to the prevalence of prescription drug use
[12,20,40]. In the present study, only 41 students (37.6%) regularly
took ADD/ADHD medications among 109 students who had ever
been diagnosed with ADD/ADHD. Of the students who were
ever diagnosed with ADD/ADHD, 36 (33%) had misused
methylphenidate. Notably, only 10 students reported recreational
use (9.2% of these students had a previous diagnosis of ADHD),
whereas 29 students reported using the medication for cognitive
enhancement (26.6%). The findings of the present study are
consistent with previous research on ADD/ADHD patients and
the misuse of their medications [36,41]. The prevalence of use of
methylphenidate for neuroenhancement purposes only slightly
changed when subjects with an ADHD diagnosis were excluded.
Therefore, the results were not confounded by ADHD diagnosis.
Female students used soft enhancers for neuroenhancement
significantly more often than male students. This finding is
consistent with a study conducted at German universities, in which
the proportion of female students who used soft enhancers to
enhance cognitive function was twice as large as in male students
[14]. Concerning the use of drugs for recreational purposes, male
students had significantly higher prevalence rates of methylphe-
nidate, caffeine tablet, energy drink, and vitamin and tonic use. A
possible explanation for these results might be that female students
Table 6. Lifetime prevalence of neuroenhancement according to substance categories and study site based on directly
cognitive-enhancing neuroenhancement substances, including methylphenidate, modafinil, antidepressants, anti-dementia
agents, beta-blockers, cocaine, and amphetamines (N = 6275).
Institution
UZH (n=404) ETHZ (n=3347) UniBas (n=2524) Total (N=6275)
Prescription drugs
Men 10.7% (11) 5.1% (104)* 7.2% (74) 5.9% (189)
Women 7.3% (22) 3.7% (48) 6.6% (98) 5.4% (168)
Total 8.2% (33) 4.5% (152) 6.8% (172) 5.7% (357)
Drugs of abuse
Men 1% (1) 0.7% (15) 0.7% (7) 0.7% (23)
Women 0.3% (1) 0.3% (4) 0.5% (7) 0.4% (12)
Total 0.5% (2) 0.6% (19) 0.6% (14) 0.6% (35)
Prescription drugs AND
drugs of abuse
Men - 0.4% (9) 0.2% (2) 0.3% (11)
Women 0.3% (1) 0.3% (4) 0.2% (3) 0.3% (8)
Total 0.2% (1) 0.4% (13) 0.2% (5) 0.3% (19)
Prescription drugs OR
drugs of abuse
Men 11.7% (12) 5.4% (110)* 7.6% (79) 6.3% (201)
Women 7.3% (22) 3.7% (48) 6.8% (102) 5.6% (172)
Total 8.4% (34) 4.7% (158) 7.2% (182) 5.9% (373)
*p,0.05,
**p,0.01,
***p,0.001, compared with women.
doi:10.1371/journal.pone.0077967.t006
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expect greater effects on cognitive performance and well-being
from soft enhancers, whereas men prefer using prescription or
illicit stimulants to improve their academic performance.
Students with experiences of illegal psychoactive substances had
generally more commonly used prescription drugs or drugs of
abuse (or both) to enhance cognitive function. This finding is
consistent with previous research on the non-medical use of
prescription stimulants [8,35]. We also confirmed that students
who used neuroenhancement showed more risky health behaviors
compared with other students [14,36].
Unlike studies in Germany, we did not find a higher prevalence
of neuroenhancement in sports students or students in the
pharmaceutical sciences or medicine compared with other study
majors [14,22]. The underlying explanation for this result should
be further investigated in future research. Neuroenhancement was
reported by fewer ETHZ students compared with the other two
universities, although the highest prevalence rate was found
among students who majored in architecture (ETHZ). A possible
explanation for this observation might be that architecture
students typically have to complete projects in a short period of
time. Previous studies may have failed to detect the high
prevalence of neuroenhancement among architecture students
because they combined all of the technical sciences [14] or did not
categorize the students by study major [2,19,22].
More senior students generally had more experience with
neuroenhancement. These findings are consistent with the findings
from German higher education institutions [14]. Only one
German study found a higher prevalence of neuroenhancement
among students in the first semester compared with senior students
[22]. Students at UZH had a higher mean age compared with the
other institutions. They had already been enrolled in education for
a longer period of time, they were more likely to have been
employed during their studies, and they had more experience with
neuroenhancement, in contrast to students from other institutions.
The higher prevalence of neuroenhancement among UZH
students likely reflects their older age, longer duration of
education, and additional job pressures as opposed to some
particular characteristic of this institution. Additionally, the
number of students from UZH was relatively small, and recruiting
at that institution was not identical to the other institutions, which
may have resulted in an additional selection bias.
Students who felt high performance pressure were more likely to
consume prescription drugs or psychoactive substances (or both) to
enhance cognitive function. High performance pressure at work
led to a higher prevalence of neuroenhancement (28%).
Compared with other students, students from UZH were more
likely to be employed and felt higher performance pressure at work
and in education simultaneously; therefore, this pressure could
explain the higher prevalence rates of neuroenhancement at UZH.
Consistent with these results, Australian university students
believed that the use of prescription and illicit stimulants was
related to attempts to manage both social life and educational
requirements [29]. The aim of neuroenhancement may be not
only to improve academic performance but also to enhance work-
life balance.
A negative relationship was found between illicit substance use
and performance pressure. Students who reported low perfor-
mance pressure in the areas of education and work reported more
illicit drug use. Therefore, students with high performance
pressure may not allow themselves to consume illicit drugs.
Our findings in this report have several limitations. First, the
study did not include information from all of the students at each
of the three Swiss institutions because not every student had
agreed to receive study invitation e-mails. This limitation was
particularly problematic for UZH but not for UniBas, where all of
the students were invited. Second, response rates from online
surveys are typically quite low and subject to selection bias.
However, response rates in the present study were as high as
23.4% and 27.1% at UniBas and ETHZ, respectively, but within
the expected low range at UZH (8.1%). Third, all of the
participants were from the German-speaking part of Switzerland
(Zurich and Basel), and the results may not be generalizable to
other Swiss universities, particularly universities in the French-
speaking part of Switzerland. However, we recruited a very
heterogeneous sample with respect to all major academic
disciplines, in contrast to earlier studies [2,22]. Finally, our
findings are limited by the use of a cross-sectional design. Thus, we
were unable to determine whether neuroenhancement and illicit
drug use in students occurred simultaneously or concurrently.
Notwithstanding these limitations, the present study also has
important strengths. The combination of three similar surveys at
three different institutions, the use of specific questions regarding
the purpose of use (i.e., recreational versus neuroenhancement),
and the broad range of substances included in the definition of
neuroenhancement are noted strengths of this study. Thus, this
study is the first large-scale study of the use of neuroenhancement
by Swiss university students and one of the more detailed and
comprehensive surveys conducted internationally.
The bioethical debate on neuroenhancement often focuses on
reasons for being more liberal with regard to neuroenhancement
or defending perspectives on neuroenhancement. Only 15.5% of
the respondents in our study were unable to imagine a justification
for neuroenhancement. However, other studies reported that most
students [42] and also some psychiatrists and general practitioners
consider neuroenhancement to be unacceptable [23]. Further
research should concentrate on more detailed descriptions of
attitudes about neuroenhancement among students and analyze
whether students consider pharmaceutical enhancement to be a
justifiable behavior, depending on subject characteristics and
context. Forty percent of the students in our study accepted the
consumption of substances for reasons such as enhancing
cognition, alertness, and memory.
Future research should also investigate the prevalence of
neuroenhancement in the general population to determine
whether only students avail themselves of neuroenhancement
strategies or whether employees and apprentices also use
prescription drugs or drugs of abuse for the same purposes. We
would also like to highlight the importance of future research that
carefully compares different studies of neuroenhancing substances
because different definitions of the term ‘‘neuroenhancement’’
exist, and the substances and purposes of use vary from study to
study. This variation explains to a large extent the different study
results with regard to the prevalence of neuroenhancement. New
trends in neuroenhancement should also be observed as they
develop, and the impact of neuroenhancement on individual
situations and behavior should be estimated [43]. If considered
necessary by university authorities, for example, health promotion
interventions could be developed and implemented based on the
empirical data presented in the present study.
Conclusions
Neuroenhancement with prescription drugs and drugs of abuse
is reported by a significant proportion of Swiss university students
across academic disciplines. However, in contrast to soft enhancers
such as coffee, these substances are rarely used on a daily basis
prior to exams. Experience with the use of illicit drugs of abuse was
associated with neuroenhancement. Nevertheless, illicit stimulants
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are primarily used in recreational contexts and rarely for
neuroenhancement purposes. Continued observations of the
development of cognitive enhancement strategies among students
should be made.
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